Theratechnologies Inc.

03/24/2021 | Press release | Distributed by Public on 03/24/2021 05:32

Theratechnologies Announces First Patient Dosed In Phase 1 Clinical Trial Of TH1902 For Sortilin Positive Solid Tumors